Superantigen-induced lysis of melanoma cells

Melanoma Research

Volumn 7, Issue 3, 1997, Pages 214-222

  Krull, F ^a   Holzer, U ^a   Ihle, J ^a   Bethge, W ^a   Fierlbeck, G ^b   Kalland, T ^c,d   Dohlsten, M ^c,d   Niethammer, D ^a   Dannecker, G E ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Pharmacia & Upjohn AB   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Cytotoxic T lymphocyte; GD3 ganglioside; Melanoma; Monoclonal antibody; Superantigen

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GANGLIOSIDE GD3; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN A; PROTEINASE; RECOMBINANT PROTEIN; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN;

ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA CELL; POINT MUTATION; PRIORITY JOURNAL;

EID: 0030837395     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199706000-00005     Document Type: Article

References (41)

1. Elwood JM, Koh HK. Etiology, epidemiology, risk factors and public health issues of melanoma. Curr Opin Oncol 1994; 6: 179-187.
2. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22: 217-226.
3. Johnson TM, Smith JW, 2nd, Nelson BR, et al. Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995; 32: 689-707.
4. Kirkwood JM. Systemic therapy of melanoma. Curr Opin Oncol 1994; 6: 204-211.
5. Strohal R, Marberger K, Pehamberger H, et al. Immunohistological analysis of anti-melanoma host responses. Arch Dermatol Res 1994; 287: 28-35.
6. Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995; 7: 175-184.
7. Garbe C. Perspectives of cytokine treatment in malignant skin tumours. Recent Results Cancer Res 1995; 139: 349-369.
8. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 1478-166.
9. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumour vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 1996; 156: 700-710.
10. Porgador A, Tzehoval E, Vadai E, et al. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res 1995; 55: 4941-4949.
11. Fleuren GJ, Gorter A, Kuppen PJK, et al. Tumour heterogeneity and immunotherapy of cancer. Immunol Rev 1995; 145: 91-122.
12. Minasian LM, Yao TJ, Steffens TA, et al. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer 1995; 75: 2251-2257.
13. Zhang S, Helling F, Lloyd KO, et al. Increased tumour cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 1995; 40: 88-94.
14. Salgaller ML, Afshar A, Marincola FM, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995; 55: 4972-4979.
15. Parmiani G, Colombo MR Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res 1995; 5: 295-301.
16. Sivam GP, Martin PJ, Reisfeld RA, et al. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res 1995; 55: 2352-2356.
17. Reisfeld RA, Gillies SD, Mendelsohn J, et al. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res 1996; 56: 1707-1712.
18. Renner C, Pfreundschuh M. Tumour therapy by immune recruitment with bispecific antibodies. Immunol Rev 1995; 145: 179-209.
19. Bernhard H, Karbach J, Strittmatter W, et al. Induction of tumour-cell lysis by bispecific antibody recognizing ganglioside GD2 and T-cell antigen CD3. Int J Cancer 1993; 55: 465-470.
20. Becker JC, Pancook JD, Gillies SD, et al. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996; 93: 2702-2707.
21. Dohlsten M, Hedlund G, Akerblom E, et al. Monoclonal antibody-targeted superantigens: a different class of anti-tumour agents. Proc Natl Acad Sci USA 1991; 88: 9287-9291.
22. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705-711.
23. Fleischer B, Scherzenmeier H. T cell Stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med 1988; 167: 1697-1707.
24. Dohlsten M, Lando PA, Hedlund G, et al. Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology 1990; 71: 96-100.
25. Cheresh DA, Harper JR, Schulz G, et al. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 1984; 81: 5767-5771.
26. Carrel S, Zografos L, Schreyer M, et al. Expression of CALLA/CD10 on human melanoma cells. Melanoma Res 1993; 3: 319-323.
27. Lynch SA, Bouchard BN, Vijayasaradhi S, et al. Antigens of melanocytes and melanoma. Cancer Metastasis Rev 1991; 10: 141-150.
28. Ihle J, Holzer U, Krull F, et al. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res 1995; 55: 623-628.
29. Akerblom E, Dohlsten M, Bryno C, et al. Preparation and characterization of conjugates of monoclonal antibodies and staphylococcal enterotoxin A using a new hydrophilic cross-linker. Bioconjug Chem 1993; 4: 455-466.
30. Nilsson B, Moks T, Jansson B, et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1987; 1: 107-113.
31. Holzer U, Bethge W, Krull F, et al. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer Immunol Immunother 1995; 41: 129-136.
32. Harel W, Shau H, Hadley CG, et al. Increased lysis of melanoma by in two-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res 1990; 50: 6311-6315.
33. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992; 3: 19-24.
34. Saleh MN, Khazaeli MH, Wheeler RH, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992; 52: 4342-4347.
35. Itoh K, Salmeron MA. Morita T, et al. Distribution of autologous tumour-specific cytotoxic T lymphocytes in human metastatic melanoma. Int J Cancer 1992; 52: 52-59.
36. + cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother 1993; 37: 15-25.
37. Litton MJ, Dohlsten M, Lando PA, et al. Antibody-targeted superantigen therapy induces tumour-infiltrating lymphocytes, excessive cytokine production and apoptosis in human colon carcinoma. Eur J Immunol 1996; 26: 1-9.
38. Dohlsten M, Hansson J, Ohlsson L, et al. Antibody-targeted superantigens are potent inducers of tumour-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 9791-9795.
39. Becker JC, Pancook JD, Gillies SD, et al. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996; 183: 2361-2366.
40. Dohlsten M, Sundstedt A, Björklund M, et al. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer 1993; 54: 482-488.
41. Dohlsten M, Abrahmsén L, Björk P, et al. Monoclonal antibody-superantigen fusion proteins: tumour-specific agents for T-cell-based tumour therapy. Proc Natl Acad Sci USA 1994; 91: 8945-8949.